Compare · AXGN vs HSDT
AXGN vs HSDT
Side-by-side comparison of Axogen Inc. (AXGN) and Solana Company (HSDT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AXGN and HSDT operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- AXGN is the larger of the two at $2.62B, about 26.4x HSDT ($99.3M).
- Over the past year, AXGN is up 226.4% and HSDT is down 70.7% - AXGN leads by 297.1 points.
- AXGN has been more active in the news (9 items in the past 4 weeks vs 5 for HSDT).
- AXGN has more recent analyst coverage (8 ratings vs 3 for HSDT).
- Company
- Axogen Inc.
- Solana Company
- Price
- $48.76+1.41%
- $1.73-3.35%
- Market cap
- $2.62B
- $99.3M
- 1M return
- +22.57%
- +1.76%
- 1Y return
- +226.37%
- -70.73%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 9
- 5
- Recent ratings
- 8
- 3
Axogen Inc.
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
Solana Company
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-implantable investigational medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.
Latest AXGN
- EVP & General Counsel Began Marc A exercised 67,500 shares at a strike of $8.16 and sold $3,195,788 worth of shares (67,500 units at $47.34) as part of a pre-agreed trading plan (SEC Form 4)
- Director Wendell Amy Mcbride exercised 13,353 shares at a strike of $14.85 and sold $646,592 worth of shares (13,353 units at $48.42) as part of a pre-agreed trading plan (SEC Form 4)
- Director Weiler Kathy Johnson sold $640,967 worth of shares (14,150 units at $45.30) as part of a pre-agreed trading plan, closing all direct ownership in the company (SEC Form 4)
- Cosmetic Surgery's Next Debate: Rebuild Tissue, Not Fill It
- SEC Form 10-Q filed by Axogen Inc.
- Axogen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Trace Biosciences Announces Strategic Investment from Axogen to Advance Clinical Development of its Nerve Trace Nerve-Specific Imaging Technology
- Axogen, Inc. Reports Second Quarter 2026 Financial Results
- Neuronetics Appoints Nir Naor Chief Financial Officer; Announces Additional Management Changes
- Axogen, Inc. to Report Second Quarter 2026 Financial Results on July 29, 2026
Latest HSDT
- SEC Form 10-Q filed by Solana Company
- Solana Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Solana Company Reports Second Quarter 2026 Financial Results
- Solana Company to Release Second Quarter 2026 Operating Results on August 14, 2026
- SEC Form 4 filed by CEO and President Chee Choon Wee
- New insider Summer Wisdom Holdings Ltd claimed ownership of 6,830,402 shares (SEC Form 3)
- Large owner Summer Wisdom Holdings Ltd disposed of 1,453,277 shares (SEC Form 4)
- Solana Company Partners with Alatau City to Advance Digital Asset Infrastructure and Blockchain Adoption in Central Asia
- Solana Company Board Unanimously Rejects Unsolicited Forward Industries Proposal
- Director Jiang Cosmo Yi exercised 1,005,040 shares at a strike of $0.00 and covered exercise/tax liability with 610 shares (SEC Form 4)